Targeting Angiogenic Factors for the Treatment of Medulloblastoma
- 12 April 2022
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 23 (6) , 864-886
Abstract
Opinion Statement Medulloblastoma (MB) is the most frequent pediatric brain tumor. Despite conventional therapy, MB patients have high mortality and morbidity rates mainly due to the incomplete understanding of the molecular and cellular processes involved in development of this cancer. Similar to other solid tumors, MB demonstrated high endothelial cell proliferation and angiogenic activity, wherein new blood vessels arise from the pre-existing vasculature, a process named angiogenesis. MB angiogenesis is considered a hallmark for MB development, progression, and metastasis emphasizing its potential target for antitumor therapy. However, angiogenesis is tightly regulated by a set of angiogenic factors making it a complex process to be targeted. Although agents targeting these factors and their receptors are early in development, the potential for their targeting may translate into improvement in the clinical care for MB patients. In this review, we focus on the most potent angiogenic factors and their corresponding receptors, highlighting their basic properties and expression in MB. We describe their contribution to MB tumorigenesis and angiogenesis and the potential therapeutic targeting of these factors.Keywords
This publication has 167 references indexed in Scilit:
- Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastomaOncogene, 2012
- A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma XenograftsMolecular Cancer Therapeutics, 2012
- Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for TherapyMolecular Cancer Therapeutics, 2012
- Itraconazole Side Chain Analogues: Structure–Activity Relationship Studies for Inhibition of Endothelial Cell Proliferation, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, and Hedgehog SignalingJournal of Medicinal Chemistry, 2011
- Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF InhibitionClinical Cancer Research, 2011
- Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cellsJournal of Neuro-Oncology, 2010
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cellsProceedings of the National Academy of Sciences, 2007
- EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain DimerizationMolecular Cell, 2003
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971